Chemical Information
Antiviral agent ID	DrugRepV_3288
Antiviral agent name	Pazopanib
IUPAC Name	5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide
SMILES (canonical)	CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N
Molecular Formula	C21H23N7O2S
Molecular Weight (g/mol)	437.522
InChl	InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)
Common Name	Pazopanib
Synonyms	GW 78603 | Pazopanibum
Structural Information
Clinical Information
Category	Antineoplastic and Immunomodulating Agents
Primary Indication (Clinical trial phases)	Approved
Biological Information
Primary Indication (Disease Category)	Non Infectious Disease
Primary Indication (Disease)	Advanced renal cell cancer | Advanced soft tissue sarcoma
Secondary Indication	Chikungunya virus (CHIKV) NA NA
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Potential drug target)	Fms-related tyrosine kinase 4
Secondary Indication (Model system) [cell lines/ animal models]	HEK-293
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Time of drug delivery)	Pre infection (1 hour)
Secondary Indication (Drug concentration)	0.13 μM
Secondary Indication (Cell based assay)	Flow cytometry
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	IC50 [ 50 % ]
Reference	Karlas A, Berre S, Couderc T, Varjak M, Braun P, Meyer M, Gangneux N, Karo-Astover L, Weege F, Rafte.A human genome-wide loss-of-function screen identifies effective chikungunya antiviral drugs..Nat Commun. 2016 May 12;7:11320. doi: 10.1038/ncomms11320. PMID:27177310
Comment	Calmodulin inhibitor pimozide and the fatty acid synthesis inhibitor TOFA, have a therapeutic effect in vivo